SOURCE: ONE Bio, Corp.

January 19, 2010 08:30 ET

ONE Bio Announces Closing of Financing and New Board Addition

MIAMI, FL--(Marketwire - January 19, 2010) - ONE Bio, Corp. ("ONE" or the "Company") (OTCBB: ONBI), an innovative company utilizing green process manufacturing to produce raw chemicals and herbal extracts, natural and health supplements and organic products, announced that it has held an initial closing ("Initial Closing") of a financing transaction entered into with certain investors including UTA Capital LLC and Udi Toledano. In Connection with the financing transaction, the investors executed a Securities Purchase and Registration Rights Agreement ("SPA") which provides that, upon the occurrence of certain events, the Company agreed to issue and the Investors agreed to purchase between Two Million Dollars ($2,000,000) and Three Million Dollars ($3,000,000) of the Company's secured 8% convertible notes ("Notes"). The Notes bear interest at a rate of 8% per annum, mature nine (9) months from the Initial Closing and provide the Investors with certain registration rights. The Notes may be convertible into Company common stock at specific prices as outlined in the transaction documents. At the Initial Closing, the Company issued to the Investors Three Hundred Thousand Dollars ($300,000) of its Notes and also issued to the Investors five (5) year warrants ("Warrants") to purchase an aggregate of 49,366 shares of the Company's common stock at an exercise price of $6.077 per share.

The Company also announced that it has appointed John Perkins, 45, as new director. Mr. Perkins is currently Senior Director, Northern and Southern Europe for Apple. Before joining Apple, Mr. Perkins held other senior management positions including, VP of Business Development, Worldwide Television/Video Division, Thomson Consumer Electronics, co-CEO and co-founder of Egencia, a successful internet start-up that was acquired by Expedia Inc., and Director of Marketing and Sales, Southern Europe for Dell Computer. Mr. Perkins was also a consultant for Bain & Company. Mr. Perkins has an MBA from the Wharton School of Business, and as well as an undergraduate business degree (BBA) from Wilfrid Laurier University. Mr. Perkins will also join the Company's audit committee. "We are pleased to have completed the financing transaction with Udi Toledano and his group. We intend to use the proceeds to pursue our organic and acquisition driven growth strategy," stated Marius Silvasan Company CEO. "I would also like to welcome John Perkins as new director. I look forward in working with John and the other recently appointed directors in the months to come. I believe we have assembled a diverse, experienced board with strong business, financial and bioengineering acumen," added Silvasan. About ONE Bio, Corp.

ONE Bio, Corp. ("ONE") (OTCBB: ONBI) (www.onehcorp.com) headquartered in Miami, FL, is an innovative company utilizing green process manufacturing to produce raw chemicals and herbal extracts, natural supplements and organic products. ONE is focused on capitalizing on the rapidly growing markets of the Asia Pacific region. Key products include widely recognized Solanesol, CoQ10, Resveratrol and 5-HTP, organic fertilizers, and organic bamboo health food and beverages. ONE's growth plan targets an aggressive acquisition driven strategy supported by strong organic growth. Through ONE, small private companies gain access to capital, experienced management and strategic insight. ONE builds strong synergies amongst all subsidiaries to enhance shareholder value. ONE is working with each subsidiary to promote organic and acquisition driven growth.

This press release includes statements that constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 (the "Reform Act"). ONE Bio, Corp. claims the protection of the safe-harbor for forward-looking statements contained in the Reform Act. These forward-looking statements are often characterized by the terms "may," "believes," "projects," "expects," or "anticipates," and do not reflect historical facts. Specific forward-looking statements contained in this press release include, but are not limited to: our successful integration of diversified growth companies, impact of the company's expansion plan, and new business development success, future financial results, development and acquisition of new product lines and services, the impact of competitive products or pricing from technological changes, the effect of economic conditions and other uncertainties. The forward-looking statements contained herein involve risks and uncertainties that could cause actual results to differ materially from the expectations contained in any such forward-looking statements. These risks include, but are not limited to: failure to manage operating expenses or integrate new companies and/or technologies, each of which could have a material impact on our business, our financial results, and the company's stock price. These risks and other factors are detailed in the Company's regular filings with the U.S. Securities and Exchange Commission. Most of these factors are difficult to predict accurately and are generally beyond the Company's control. Forward-looking statements speak only as to the date they are made and ONE Bio, Corp. does not undertake to update forward-looking statements to reflect circumstances or events that occur after the date the forward-looking statements are made.

Contact Information

  • Contact:
    Investor Relations & Corporate Communications

    877-544-2288
    ir@onehcorp.com

    Company and Investor Relation Contact:
    Jeanne Chan
    Senior VP
    Tel. +877.544.2288
    jchan@onehcorp.com